Exelixis
EXEL
$0.07 (0.18%)
1D
1W
3M
1Y
5Y
ALL
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 1 day ago • EXEL
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-TermZacks Investment Research • 6 days ago • EXEL
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 9 days ago • EXEL
Why Exelixis (EXEL) is a Top Value Stock for the Long-TermThe Motley Fool • 15 days ago • EXEL
The Smartest Biotech Stocks to Buy With $50Zacks Investment Research • 21 days ago • EXEL
FDA Expands Exelixis Cabometyx Label for Neuroendocrine TumorsCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.